Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Chief Financial Officer | March 15, 2022 | March 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Insight Molecular Diagnostics Inc.
Report date March 15, 2022 · Filed March 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2032-03-15 | Direct | 87,500 |
Reported balance
After 2022-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-15 · Grant · Acquired 87,500 · Balance 87,500 F1: 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2032-03-15 | Direct | 87,500 |
Reported balance
After 2022-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-15 · Grant · Acquired 87,500 · Balance 87,500 F2: Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F2: Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2022 Filed Mar 15, 2022 16:19 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 25,000 | $1.17 | $29,150.00 |
DisclosureSEC source: 0001493152-22-006879 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,080 F1 · price: The price of $1.166 per share represents a weighted average of prices ranging from $1.155 to $1.180 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:21 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 87,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-007198 · ownership.xml · derivative · entry 2 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-03-15 F2 · derivative.exercise_date: Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:21 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 87,500 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-22-007198 · ownership.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-03-15 F1 · derivative.exercise_date: 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 19:09 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-010271 · ownership.xml · derivative · entry 3 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Restricted Stock Units vested on April 28, 2021. F2 · derivative.expiration_date: Restricted Stock Units vested on April 28, 2021. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 19:09 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Tax withholdingCommon Shares, no par value | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-010271 · ownership.xml · nonDerivative · entry 2 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,080 F1 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,000 Restricted Stock Units, the grant of which was previously reported on a Form 4. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 19:09 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Shares, no par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-010271 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 16:32 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantEmployee Stock Option (right to buy) · Derivative | 255,000 | $5.34 Strike: $5.34 | $1,361,700.00 |
DisclosureSEC source: 0001493152-21-005103 · ownership.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2031-02-24 F1 · derivative.exercise_date: Vesting: Twenty-five percent of the options will vest and thereby become exercisable upon completion of one year of service from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, subject to his continued service as an employee on the applicable vesting date. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 06:13 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantCommon Stock | 10,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-20-023583 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,700 F1 · price: The shares of the Issuer's common stock were issued to the Reporting Person for the repayment of deferred compensation in lieu of cash at a price of $2.07 per share. Read SEC document |
| September 12, 2020 Filed Dec 15, 2020 06:02 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 10,000 | $2.01 | $20,060.00 |
DisclosureSEC source: 0001493152-20-023578 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,495 F1 · price: The price of $2.006 per share represents a weighted average of prices ranging from $2.003 to $2.006 per share. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price. F2 · balance_after: This Form 4 is being filed to amend the prior Form 4 filed by the Reporting Person on September 12, 2019, which erroneously did not combine the shares of common stock acquired by the Reporting Person on September 12, 2019 with the Reporting Person's common stock reported on his Form 4 on July 31, 2018. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 18:47 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 10,000 | $1.32 | $13,200.00 |
DisclosureSEC source: 0001493152-20-014611 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,579 F1 · price: 2,500.000 shares purchased at $1.3165; 2,500.000 shares purchased at $1.3058; 2,500.000 shares purchased at $1.3169; and 2,500.000 shares purchased at $1.3425. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 20:08 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-007488 · ownership.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units under the OncoCyte 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. F2 · derivative.expiration_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 17:53 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-007476 · ownership.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Grant of restricted stock units under the OncoCyte 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. F2 · derivative.expiration_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. Read SEC document |
| March 14, 2020 Filed Apr 20, 2020 16:42 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-006754 · ownership.xml · derivative · entry 3 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Restricted Stock Units vested on March 14, 2020 F2 · derivative.expiration_date: Restricted Stock Units vested on March 14, 2020 Read SEC document |
| March 14, 2020 Filed Apr 20, 2020 16:42 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Tax withholdingCommon Shares, no par value | 6,916 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-006754 · ownership.xml · nonDerivative · entry 2 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,579 F1 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,000 Restricted Stock Units, the grant of which was previously reported on a Form 4. Read SEC document |
| March 14, 2020 Filed Apr 20, 2020 16:42 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | Exercise / conversionCommon Shares, no par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-006754 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:54 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to purchase common stock · Derivative | 204,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001493152-20-002156 · ownership.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Stock · 204,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on February 10, 2020 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date. Read SEC document |
| September 12, 2019 Filed Sep 12, 2019 18:33 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock, no par value | 10,000 | $2.01 | $20,060.00 |
DisclosureSEC source: 0001209191-19-049377 · doc4.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price of $2.006 per share represents a weighted average of prices ranging from $2.003 to $2.006 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| September 12, 2019 Filed Dec 17, 2020 17:02 UTC Amendment | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon Stock | 10,000 | $2.01 | $20,060.00 |
DisclosureSEC source: 0001493152-20-023851 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,495 F1 · price: The price of $2.006 per share represents a weighted average of prices ranging from $2.003 to $2.006 per share. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price. F2 · balance_after: This Form 4 is being filed to amend the prior Form 4 filed by the Reporting Person on September 12, 2019, which erroneously did not combine the shares of common stock acquired by the Reporting Person on September 12, 2019 with the Reporting Person's common stock reported on his Form 4 on July 31, 2018. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:02 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-020138 · doc4.xml · derivative · entry 2 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Grant of restricted stock units under the OncoCye 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock. F3 · derivative.exercise_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. F3 · derivative.expiration_date: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:02 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 245,000 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001209191-19-020138 · doc4.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Underlying: Common Stock · 245,000 shares Expires 2019-03-13 F1 · derivative.exercise_date: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date. Read SEC document |
| July 26, 2018 Filed Jul 31, 2018 21:39 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock purchase warrants · Derivative | 3,495 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001493152-18-010764 · ownership.xml · derivative · entry 2 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,495 Underlying: Common stock · 3,495 shares Expires 2024-02-01 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| July 26, 2018 Filed Jul 31, 2018 21:39 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | PurchaseCommon stock, no par value | 3,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-010764 · ownership.xml · nonDerivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,495 F1 · price: The shares of common stock and the common stock purchase warrants reported in this Form were purchased in "units," with each unit consisting of one share of common stock and one common stock purchase warrant. The purchase price per unit was $2.86. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 18:00 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-18-038141 · doc4.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: One half of the options shall vest upon acceptance of the completion of the clinical validation study manuscript for OncoCyte's DetermaVu product candidate, and the balance shall vest upon the start of the clinical utility study for OncoCyte's DetermaVu product candidate. Read SEC document |
| May 23, 2018 Filed Jun 1, 2018 21:26 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 125,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-18-034891 · doc4.xml · derivative · entry 2 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-05-22 F2 · derivative.exercise_date: These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate. Read SEC document |
| May 23, 2018 Filed Jun 1, 2018 21:26 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-18-034891 · doc4.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: One quarter of the options shall vest on the one-year anniversary of the grant date and the balance shall vest thereafter in 36 equal monthly installments. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 20:01 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-17-061662 · doc4.xml · derivative · entry 1 Levine Mitchell S · CIK 0001383492 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-11-14 F1 · derivative.exercise_date: One quarter of the options shall vest on November 14, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.